Ethnic differences which may affect safety/tolerability. Konstanze Diefenbach 23. AGAH-Annual Meeting (13 March 2014)
|
|
- Christopher Quinn
- 6 years ago
- Views:
Transcription
1 Ethnic differences which may affect safety/tolerability Konstanze Diefenbach 23. AGAH-Annual Meeting (13 March 2014)
2 Contents Ethnic factors Introduction into ICH-E5 Definition of ethnic factors Sensitivity to ethnic factors Case examples Moxifloxacin Warfarin Carboplatin Leflunomide Summary and Conclusion Disclaimer: The information, views, and opinions contained in this presentation are those of the author and do not necessarily reflect the views and opinions of Bayer HealthCare. 2
3 3 ETHNIC FACTORS
4 ICH-E5 To facilitate the registration of medicines among ICH regions To provide guidance on regulatory and development strategies Extrapolate foreign data to different populations Evaluate influence of ethnic factors on safety, efficacy, dose and dose regimen Minimize duplication of clinical studies Describe the use of bridging studies bridge CDP in original region? Approval in the new region Before extrapolation can be considered, the Complete Clinical Data Package, including foreign clinical data, submitted to the new region should contain: Adequate characterization of pharmacokinetics*, pharmacodynamics*, doseresponse, efficacy and safety in the population of the foreign region(s). Clinical trials establishing dose response, efficacy and safety 4
5 Ethnic Factors - definition ICH-E5 points out that the influence of intrinsic and extrinsic ethnic factors on the drug's efficacy and safety should be evaluated through the development process Intrinsic Ethnic Factors: genetic and physiologic characteristics Intrinsic ethnic factors are factors that help to define and identify a sub-population and may influence the ability to extrapolate clinical data between regions Extrinsic Ethnic Factors: cultural and environmental characteristics Extrinsic ethnic factors are factors associated with the environment and culture in which a person resides. Extrinsic factors tend to be less genetically and more culturally and behaviorally determined. 5
6 6 Ethnic Factors - definition
7 Sensitivity to Ethnic Factors Sensitivity to Ethnic Factors Less sensitive More Sensitive Pharmacokinetics (PK) Linear Non-linear Linear PK Non-linear PK Rate of elimination or Exposure Rate of elimination Exposure Dose Dose Dose 7
8 Sensitivity to Ethnic Factors Sensitivity to Ethnic Factors Less sensitive More Sensitive Pharmacokinetics (PK) Linear Non-linear Pharmacodynamics (PD) curve for both efficacy and safety Flat Steep Effect Flat PD curve Effect Steep PD curve Conc. Conc. 8
9 Sensitivity to Ethnic Factors Sensitivity to Ethnic Factors Less sensitive More Sensitive Pharmacokinetics (PK) Linear Non-linear Pharmacodynamics (PD) curve for both efficacy and safety Therapeutic dose range (possibly an indicator of good tolerability Flat Wide Steep Narrow 9
10 Sensitivity to Ethnic Factors Sensitivity to Ethnic Factors Less sensitive More Sensitive Pharmacokinetics (PK) Linear Non-linear Pharmacodynamics (PD) curve for both efficacy and safety Therapeutic dose range (possibly an indicator of good tolerability Flat Wide Steep Narrow Metabolism Minimal or multiple pathways Highly or single pathway; Metabolism by enzymes known to show genetic polymorphism Bioavailability High (less susceptibility to dietary absorption effects) Protein binding Low High Low (more susceptible to dietary absorption effects) Drug-drug, drug-diet, and drugdisease Little potential Highly likelihood interactions Mode of action Non-systemic Systemic Inappropriate use Little potential Highly likelihood Multiple co-medications Little potential Highly likelihood 10
11 11 CASE 1: MOXIFLOXACIN
12 Case 1: Moxifloxacin Ethnic difference in PK? Japan, China, Korea Tripartite co-operation 12 Research on ethnic factors: 1 st Stage: Literature-based PK comparison among populations Part of ethnic variability explained by the frequency differences in functional genetic polymorphisms of the drug metabolizing enzymes and transporters. Involvement of other factors in PK differences among populations has been suggested in some drugs: Moxifloxacin, Simvastatin and Meloxicam. 2 nd Stage: Prospective PK study
13 Case 1: Moxifloxacin Ethnic difference in PK? Ethnic Factors Less sensitive Moxifloxacin Pharmacokinetics (PK) Linear Pharmacokinetics are linear in the range of 50 to 1200 mg single dose Pharmacodynamics (PD) curve for both efficacy and safety Flat Meta-analysis of 4926 patients indicated that AEs were mostly mild and transient. The most frequent events were nausea (7.2%) and diarrhoea (5.7%). Therapeutic dose range (possibly an indicator of good tolerability) Metabolism Wide SD 50 to 800 mg or MD up to 600mg once daily for 10 days well tolerated in healthy volunteers (n = 103). Minimal or multiple pathways Moxifloxacin and Phase II metabolites yielded 96~98% regardless of administration, no oxidative metabolism. Bioavailability High (less susceptibility to dietary absorption effects) Absolute bioavailability about 91% and no food effect on the PK of moxifloxacin. Protein binding Low Protein binding about 45 %, mainly bound to serum albumin Drug-drug, drug-diet, and drug-disease interactions Mode of action Little potential Non-systemic No CYP related DDI Inappropriate use Little potential Little potential Multiple co-medications 13 Little potential
14 Case 1: Moxifloxacin Ethnic difference in PK? Bayer Data (Revised by NIHS) 0.2 Relative AUC difference Chinese Caucasian Compared with Japanese 90%CI 14
15 Case 1: Moxifloxacin Ethnic difference in PK? Country Site PI Japan Kitasato University Tomoko Hasunuma China Peking University First Hospital Cui Yimin Korea Seoul National University In-Jun Jang 15 US SNBL Baltimore Masaru Kaneko
16 Case 1: Moxifloxacin Ethnic difference in PK? Moxifloxacin PK Data (AUC) Data from Bayer IMCT trial A single protocol controlling for extrinsic was employed and uniformly applied to the study populations to assess ethnic differences in PK Recommended to assess genotypes of study subjects study populations to assess ethnic differences in PK as polymorphisms of the relevant genes may affects drug PK 16
17 17 CASE 2: WARFARIN
18 Case 2: Warfarin Ethnic difference in PK and PD Influence of ethnicity on warfarin dose requirement to achieve a target INR 2-3 Warfarin label: Individualization by monitoring the PT/INR. Maintenance dose to achieve a target PT/INR is influenced by: Age Race/ethnicity Body weight Sex Concomitant medications, Comorbidities Genetic factors (CYP2C9 and VKORC1 variants) Dang et al. Ann Pharmacother 2005;39:
19 Case 2: Warfarin Ethnic difference in PK and PD Mechanism of warfarin and its metabolism CYP2C9: CYP2C9 is the key enzyme in metabolism of the more potent S- warfarin VKORC1: VKOR is the target enzyme for warfarin to exert its anticoagulation effect VKOR is inhibited by warfarin to regenerate the reduced vitamin K from its epoxide form Tan GM, Wu E, Lam YY, Yan BP. Pharmacogenomics. 2010;11(3): Several other genes may influence variation in warfarin metabolism 19
20 Case 2: Warfarin Ethnic difference in PK and PD CYP2C9 variants (*2 and *3): Nonsynonymous coding variants resulting in reduced enzyme activity and decreased metabolic capacity Variants more common in Whites VKORC1 variant(s) ( 1639G>A, 1173C>T): Effects thought to be mediated through differential expression of the VKOR protein Variability in warfarin dose captured by a single polymorphism - strong linkage equilibrium between the variants Variant allels associated with a lower warfarin dose Johnson JA. Circulation : Variant allels very common in Asian 20
21 Case 2: Warfarin Ethnic difference in PK and PD CYP2C9 variants (*2 and *3): Nonsynonymous coding variants resulting in reduced enzyme activity and decreased FDA metabolic approvd capacity label COUMADIN (warfarin sodium) tablets contains Variants now morethe common following Whites table: VKORC1 variants: Effects thought to be mediated through differential expression of the VKOR protein (warfarin target: vitamin K epoxide reductase) Variability in warfarin dose captured by a single polymorphism - strong linkage equilibrium between variants Variant allels associated with a lower warfarin dose Variant allels very common in Asian 21
22 Case 2: Warfarin Ethnic difference in safety? In global trials, INR range of 2 3 established to balance benefits (reduced thromboembolic events) with risks (bleeding) for warfarin Large trials predominantly in Caucasian Data suggest it may not be the most appropriate INR range in Asians You et al. 2005: In 491 Chinese patients treated with warfarin, INR associated with the lowest hemorrhagic and thromboembolic rate was 1.8 to 2.4 Suzuki et al. 2007: In 667 Japanese treated with low-dose warfarin therapy (target INR 1.6 to 2.6) for non-valvular atrial fibrillation, rate of major bleeding/intracranial hemorrhage patients is similar to the rate observed in Western populations with fulldose anticoagulation (target INR 2 to 3) and about 2fold the rate observed in Western populations for low-intensity warfarin therapy Yu et al. 2005: In 563 Taiwanese patients with mechanical valve replacements (INR 2.5 to 3.5, risks of thromboembolism not different with an INR<2 versus >2) Asians may have greater thromboembolic protection at lower INRs than Caucasian and might be at increased risk of bleeding at lower INRs 22 Review on Ethnic difference in cardiovascuar drug response : Johnson JA. Circulation :
23 23 CASE 3: CARBOPLATIN
24 Case 3: Carboplatin-induced myelosuppression Neutropenia in NSCLC studies: Combination of paclitaxel (225 mg/m 2 ) and carboplatin AUC 6 Kelly 1999 (SWOG): Grade 4 neutropenia in 35% of 188 patients Shiller 2000 (ECOG): Grade 4 neutropenia in 42% of 272 patients Ogawara 2002: Grade 4 neutropenia in 70% of 10 patients Neutropenia in epitelial ovarian cancer: Combination of paclitaxel (175 mg/m 2 ) and carboplatin AUC = 5 Takei 2003: Grade 4 neutropenia (80% in the Japanese cohort) was dose-limiting Neutropenia in NSCLC studies: Combination of docetaxel (75 mg/m 2 ) and carboplatin AUC 6 Millward 2003: Phase II study in Caucasian and Asian patients (Singapore), Grade 4 neutropenia in 70% (26% febrile neutropenia) Reduction to carboplatin AUC 4.5 at Singapore site due to high rate of febrile neutropenia: 50% febrile neutropenia at AUC 6, 40% febrile neutropenia at AUC 4.5 2/2 Asian patients at Australia site developed grade 4 neutropenia Possible explanations for susceptibility of Asians to platinum-based chemotherapies: Genetic causes, and/or differences in environmental factors, local treatment practice, and/or unique drug drug interactions 24
25 Case 3: Carboplatin-induced myelosuppression Ethnic diversity in drug response or toxicity, results from the combined interaction of many factors, principally differences in environment, local practice habit and regulatory control differences, drug drug interaction differences, and genetic differences 25 O'Donnell PH, Dolan ME. Clin Cancer Res 2009;15:
26 26 CASE 4: LEFLUNOMIDE
27 Case 4: Leflunomide Leflunomide (Arava ) Immunosuppressive disease-modifying antirheumatic drug to be used in active moderate to severe rheumatoid arthritis and psoriatic arthritis Available for oral administration as tablets containing 10, 20, or 100 mg rheuma-online.de 27
28 Case 4: Leflunomide Ethnic difference in DILD PK comparison after a single dose of 20 mg in Japanese and Caucasian No Major Differences on PK in leflunomide administration Similar PK have been also confirmed in multiple administration 28 Taken from: Shinobu Uzu, MHLW (Japan s experience with ICH and the implementation of Guidelines)
29 Case 4: Leflunomide Ethnic difference in DILD Conclusion from PMDA review on leflunomide in Japan Foreign data can be extrapolated into Japanese populations in terms of doseresponse effects of leflunomide However, risks in hepatotoxicity, bone marrow suppression as well as infectious diseases were identified In terms of safety, because of small sample size in Japanese, it is difficult to conclude that safety profiles of leflunomide in Japanese are similar to foreign population. Leflunomide was approved with condition (intensive post-market surveillance) Post-marketing surveillance of leflunomide All leflunomide-administered patients must be registered into the survey before starting leflunomide therapy Serious cases of interstitial lung diseases (ILD) have been reported 5 death cases in 3 month after launch. 16 ILD cases in 3412 patients enrolled in the survey Box Warning in the label were revised to increase the precaution level about ILD 29 Taken from: Shinobu Uzu, MHLW (Japan s experience with ICH and the implementation of Guidelines)
30 Case 4: Leflunomide Ethnic difference in DILD Azuma A, Japan Med Associate J, 50: , Page 30
31 Case 4: Leflunomide Ethnic difference in DILD Possible explanations for differences in DILD: Potential ethnic or genetic differences between the Japanese population and the other populations: Acute exacerbations of idiopathic pulmonary fibrosis are more frequent and severe in Japanese patients (Azuma et al. 2007) Single nucleotide polymorphisms of surfactant protein D and interstitial pneumonia in Japanese population (Ishii et al. 2012) Differences in the methods used in the studies e.g. difference in the system for collecting information about AE in the post-marketing setting In Japan, active solicitation of DILD required in early phase of launch of new drugs under the Early Post-marketing Phase Vigilance (EPPV) requirement of the Japanese Health Authority, and high incidence of DILD in Japan may be because of the greater awareness about DILD (Horiuchi-Yamamoto et al. 2012) Worldwide reporting frequency basically estimated from spontaneous reports or literature reports 31
32 32 SUMMARY AND CONCLUSION
33 Summary and conclusion Some properties of a drug (e.g. chemical class, metabolic pathway, pharmacologic class) make it more or less likely to be affected by ethnic factors Characterization of a drug according to the potential impact of ethnic factors, requires: Knowledge of PK and PD properties and its inter-relationship Assessment if bridging PK and PD into clinical effectiveness and safety is adequate Careful evaluation of potential intrinsic and extrinsic factors (ethnic sensitivity report) Be prepared for the unexpected 33
34 Thank you for your attention Questions? 34
Warfarin Dosing Using Genetic Information A Model for Hospital Policy Development
Warfarin Dosing Using Genetic Information A Model for Hospital Policy Development Jean Lopategui, MD Director, Molecular Pathology Jean.lopategui@cshs.org Warfarin Pharmacogenomics Part I Background Information
More informationAnticoagulant Treatments for Special Patient Populations
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-pharmacy/anticoagulant-treatments-for-special-patientpopulations/3796/
More informationPharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
More informationPharmacogenomic Testing for Warfarin Response (NCD 90.1)
Policy Number 90.1 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationRisk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response
Risk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response 2003 FDA/Industry Statistics Workshop Peter I. Lee, PhD Associate Director, Pharmacometrics OCPB, CDER, FDA Disclaimers
More informationModeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients
Modeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients Eva Bredberg, Director Global Clinical Pharmacology, AstraZeneca On behalf of EFPIA EMA Geriatrics Workshop
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 12/16/10, 12/15/11, 12/20/12, 12/19/13
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationRecent experiences to review data from MRCTs and progress of research on ethnic factors. Dr Yoshiaki Uyama
Recent experiences to review data from MRCTs and progress of research on ethnic factors Dr Yoshiaki Uyama (PMDA) Visiting Professor, Graduate School of Advanced Clinical Science, Chiba University Visiting
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 12/16/10, 12/15/11, 12/20/12, 12/19/13, 12/18/14
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationCase Report Warfarin Dosing in a Patient with CYP2C9 3 3 and VKORC AA Genotypes
Case Reports in Genetics, Article ID 413743, 4 pages http://dx.doi.org/10.1155/2014/413743 Case Report Warfarin Dosing in a Patient with CYP2C9 3 3 and VKORC1-1639 AA Genotypes Mark Johnson, 1 Craig Richard,
More informationThe WARFARIN Study: Genetic Testing and Systems Reengineering to Support Personalized Medicine
The WARFARIN Study: Genetic Testing and Systems Reengineering to Support Personalized Medicine Elizabeth O. Ofili, M.D., M.P.H., F.A.C.C. Professor of Medicine and Chief of Cardiology Associate Dean, Clinical
More informationSYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.
Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and
More informationJapanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity
Clinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity Clinical Policy Number: 02.01.13 Effective Date: September 1, 2013 Initial Review Date: May 15, 2013 Most Recent Review
More informationSummary of the risk management plan (RMP) for Zykadia (ceritinib)
EMA/154751/2015 Summary of the risk management plan (RMP) for Zykadia (ceritinib) This is a summary of the risk management plan (RMP) for Zykadia, which details the measures to be taken in order to ensure
More informationMEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 (CYP2C9) AND VITAMIN K EPOXIDE REDUCTASE SUBUNIT CI (VKORC) THAT AFFECT RESPONSE TO WARFARIN
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationUtility of Pharmacogenomics to Identify and Limit CV Risk. Christopher B. Granger, MD
Utility of Pharmacogenomics to Identify and Limit CV Risk Christopher B. Granger, MD Disclosure Research contracts: AstraZeneca, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company, and Boehringer
More informationA COhort of antithrombotic use and. atrial fibrillation in Thailand (COOL AF Thailand)
A COhort of antithrombotic use and Optimal INR Level in patients with nonvalvular atrial fibrillation in Thailand (COOL AF Thailand) Prevalence of Atrial Fibrillation Number of AF Patients Predicted to
More information2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market
Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationUSING GENETICS TO DRIVE TREATMENT: A FOCUS WARFARIN
Volume 23, Issue 10 July 2008 USING GENETICS TO DRIVE TREATMENT: A FOCUS ON WARFARIN Gregory J. Welder, Pharm.D. candidate The use of genetics in health care has become a mechanism for identifying risk.
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationNew Horizons in Anticoagulation: The Way of the Future. Disclosure. Outline. The speaker has nothing to disclose in relation to this presentation
New Horizons in Anticoagulation: The Way of the Future Gloria Grice Pharm.D., BCPS St. Louis College of Pharmacy & Barnes-Jewish Hospital Anticoagulation Service Disclosure The speaker has nothing to disclose
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationSub Population: The elderly
Sub Population: The elderly How can Modelling and Simulation inform understanding of safety and efficacy? Amy S. Y. Cheung, Senior Clinical Pharmacometrician Early Clinical Development, AstraZeneca On
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationReview Report. February 22, 2017 Pharmaceuticals and Medical Devices Agency
Review Report February 22, 2017 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted
More informationHypertension Clinical Trials. in China. Liu Lisheng
Hypertension Clinical Trials in China Liu Lisheng Necessity of Conducting Large-scale Clinical Studies using Chinese Subjects RCT in China Discussion Experience Pharmacogenetics & individualized medicine
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Vfend /Voriconazole
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationPHARMACOGENETICS. Marshalling the human genome to individualize drug therapy
PHARMACOGENETICS Marshalling the human genome to individualize drug therapy Prof. Ronen Loebstein Institute of Clinical Pharmacology & Toxicology Sheba Medical Center Some examples of drug response rates
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationFDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
October 12, 2012 FDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationThe Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (5), Page
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (5), Page 6646-6654 The Impact of "CYP2C9" and "VKORC1" Genetic Polymorphism upon Oral Anticoagulation Requirements Hossam Yousef Kamal
More informationICH Topic E 5 (R1) Questions and Answers Ethnic Factors in the Acceptability of Foreign Clinical Data. Step 5 QUESTIONS AND ANSWERS (CPMP/ICH/289/95)
European Medicines Agency June 2006 CPMP/ICH/5746/03 ICH Topic E 5 (R1) Questions and Answers Ethnic Factors in the Acceptability of Foreign Clinical Data Step 5 QUESTIONS AND ANSWERS (CPMP/ICH/289/95)
More informationGan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur
Gan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur outline Definitions Genetic polymorphisms and drugs therapy a)warfarin b) Mercaptopurine c) Methotrexate d) Clopidogrel e) others
More informationGenomics in patients with Japanese Ancestry
Genomics in patients with Japanese Ancestry Yoshiaki Uyama, Ph.D. (PMDA) Visiting Professor, Graduate School of Medicine, Chiba University Visiting Professor, Graduate School of Medicine, Nagoya University
More informationReview Report. August 22, 2017 Pharmaceuticals and Medical Devices Agency
Review Report August 22, 2017 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted by
More informationFamily Medicine Clinical Pharmacy Forum Vol. 4, Issue 5 (September/October 2008)
1 Family Medicine Clinical Pharmacy Forum Vol. 4, Issue 5 (September/October 2008) Family Medicine Clinical Pharmacy Forum is a brief bi-monthly publication from the Family Medicine clinical pharmacists
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationTailoring Drug Therapy Based on Genotype. Larisa H. Cavallari, Pharm.D. Associate Professor, Department of Pharmacy Practice
Tailoring Drug Therapy Based on Genotype Larisa H. Cavallari, Pharm.D. Associate Professor, Department of Pharmacy Practice University of Illinois at Chicago 833 S. Wood St., Rm 164 Chicago, IL 60612 Tel:
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationPeking University Asia Pacific Economic Cooperation Regulatory Sciences Center of Excellence APEC CENTER OF EXCELLENCE PILOT WORKSHOP
Peking University Asia Pacific Economic Cooperation Regulatory Sciences Center of Excellence APEC CENTER OF EXCELLENCE PILOT WORKSHOP MULTI-REGIONAL CLINICAL TRIALS AND INCORPORATING GCP-RELATED CONSIDERATIONS
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationA unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure
A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Sylvain Goutelle, Michel Tod, Laurent Bourguignon, Nathalie Bleyzac,
More informationREVISITING THE PHARMACOKINETICS IN PATIENTS
REVISITING THE PHARMACOKINETICS IN PATIENTS WITH IMPAIRED RENAL FUNCTION IN THE LIGHT OF THE LATEST FDA AND EMA GUIDELINES 3 RD CONFERENCE OF EUROPEAN PHARMACOLOGICAL SOCIETIES EUROPEAN COMPETITIVENESS
More informationScientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles
Scientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles Liang Zhao, Ph.D. Director, Division of Quantitative
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationSummary of the risk management plan (RMP) for Neofordex (dexamethasone)
EMA/934/2016 Summary of the risk management plan (RMP) for Neofordex (dexamethasone) This is a summary of the risk management plan (RMP) for Neofordex, which details the measures to be taken in order to
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More information1.0 Abstract. Title. Keywords. Adalimumab, Rheumatoid Arthritis, Effectiveness, Safety. Rationale and Background
1.0 Abstract Title Assessment of the safety of adalimumab in rheumatoid arthritis (RA) patients showing rapid progression of structural damage of the joints, who have no prior history of treatment with
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationSubject: Important Safety Information: Intracranial Hemorrhage in Patients Receiving Aptivus (tipranavir) capsules
Subject: Important Safety Information: Intracranial Hemorrhage in Patients Receiving Aptivus (tipranavir) capsules Dear Healthcare Professional: Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationAubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subsection: Endocrine and Metabolic Drugs Original Policy Date: April 1, 2013 Subject: Aubagio
More informationPredict GENES. Select right drug. Select right dose. Develop new drugs. Non-Response Response Adverse Reaction
Predict Select right drug Select right dose Develop new drugs GENES Non-Response Response Adverse Reaction Phase I: Each Chromosome Has Many Genes Chromosome 12 ~ 1,300 Genes Examples of Personalized Medicines
More informationPublic Assessment Report Scientific discussion. Metoject Metojectpen (methotrexate disodium) SE/H/643/01/DC SE/H/643/02-11/DC
Public Assessment Report Scientific discussion Metoject Metojectpen (methotrexate disodium) SE/H/643/01/DC SE/H/643/02-11/DC This module reflects the scientific discussion for the approval of Metoject
More informationGWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy
GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients (short title: RWDD3 and TECTA variants in ovarian
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationPossible causes of difference among regions How to look at the results from MRCT Non-compliance with GCP and/or protocol Apparent Differences (Play of
Outline ICH E17 General Principles for Planning and Design of Multi-Regional Clinical Trials Future MRCTs Based on E17 Guideline Background and Key Principles in E17 Some case studies of Gastric Cancer
More informationUNDERSTANDING HAIR THINNING/HAIR LOSS
UNDERSTANDING HAIR THINNING/HAIR LOSS INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. IMPORTANT SAFETY INFORMATION WARNING: HEPATOTOXICITY
More informationPMDA Considerations for Outcome Assessments
PMDA Considerations for Outcome Assessments Keiju Motohashi Office of New Drug II Pharmaceuticals and Medical Devices Agency/ The University of Tokyo Hospital Disclaimer The views and opinions expressed
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationResults. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study
Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth
More informationEMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - PANCYTOPENIA AND SERIOUS SKIN REACTIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 October 1999 EMEA/31637/99 EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - PANCYTOPENIA AND
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationBreast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer
Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast
More informationStopping rules for FIM trials
Stopping rules for FIM trials AGAH Workshop, 26 September 2013 Dr. Karin Göhler, Grünenthal GmbH Page 1 Relevant Guidelines EMEA/ CHMP/ SWP/ 294648/ 2007 Guideline on strategies to identify and mitigate
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationBreast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer
Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer Indication: Neoadjuvant therapy for patients with BRCA1/2 mutations EC Regimen details:
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationFUJI study: Follow-Up of Jevtana in real life
Pharmacologie médicale Bordeaux PharmacoEpi CIC Bordeaux CIC1401 FUJI study: Follow-Up of Jevtana in real life French retrospective and protective multicenter observational study describing the survival,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationAubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.09 Subject: Aubagio Page: 1 of 6 Last Review Date: June 22, 2017 Aubagio Description Aubagio (teriflunomide)
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More information1. Immediate 2. Delayed 3. Cumulative
1 Pharmacodynamic Principles and the Time Course of Delayed Drug Effects Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand The time course of drug action combines
More informationCONSISTENT FDA APPROVED
FLEXIBLE ACCURATE Exactly what ALL * patients need. CONSISTENT FDA APPROVED * Acute lymphoblastic leukemia. What is PURIXAN? PURIXAN (mercaptopurine) oral suspension is indicated for the treatment of patients
More informationExperimental and clinical pharmacology. Pharmacogenetics of warfarin is testing clinically indicated?
Experimental and clinical pharmacology Pharmacogenetics of warfarin is testing clinically indicated? Jennifer H Martin, Clinical Pharmacologist and General Physician, Departments of Medicine and Chemical
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationWarfarin Management-Review
Warfarin Management-Review December 18, 2012 Elaine M. Hylek, MD, MPH Director, Thrombosis Clinic and Anticoagulation Service Boston University Medical Center Areas for Discussion Implications of time
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationBreast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen
More information